3 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
Follow Down Syndrome: new trials by email Literature Review of Down Syndrome trials Research Report on Down Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome Sargramostim for Injection, Saline Placebo - Down Syndrome | Phase 2 | Withdrawn | University of Colorado, Denver | 2023-10-23 | 2025-04-02 | |
| A Study of ACI-24 in Adults With Down Syndrome ACI-24, Placebo - Down Syndrome | Phase 2 | Withdrawn | AC Immune SA | 2021-10-01 | 2021-10-22 | |
| Liq-NOL Efficacy in Pediatric Patients With Down Syndrome Ubiquinol-10 Syrup, syrup (placebo) - Down Syndrome | Phase 2 | Withdrawn | Children's Hospital Medical Center, Cincinnati | 2005-01-01 | 2020-09-09 |
Behavior (1) · Cognitive Dysfunction (1) · Language (1)
Abnormalities, Multiple (3) · Chromosome Disorders (3) · Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Intellectual Disability (3) · Nervous System Diseases (3) · Neurobehavioral Manifestations (3) · Neurologic Manifestations (3) · Cognition Disorders (1) · Communication (1) · Mental Disorders (1) · Neurocognitive Disorders (1)
Granulocyte-Macrophage Colony-Stimulating Factor (1) · Injections (1) · sargramostim (1)
AC Immune SA (1) · Children's Hospital Medical Center, Cincinnati (1) · University of Colorado, Denver (1)
United States (2)
Francis Hickey, M.D. (1) · Michael S. Rafii, MD, PhD (1) · Michael V Miles, Pharm.D. (1) · Peter Pressman, MD (1)
R61AG074859 (1)